Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.8500 (-2.01%) ($5.8300 - $6.0900) on Fri. Sep. 6, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.77% (three month average) | RSI | 30 | Latest Price | $5.8500(-2.01%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -1.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(11%) LQD(6%) VCIT(6%) SHY(5%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.385% in a week (0% probabilities). URA(-9%) INDA(-9%) XLE(-8%) USO(-7%) REMX(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.385% (StdDev 2.77%) | Hourly BBV | 0 () | Intraday Trend | -2% | | | |
|
Resistance Level | $6.12 | 5 Day Moving Average | $6.02(-2.82%) | 10 Day Moving Average | $6.03(-2.99%) | 20 Day Moving Average | $6.12(-4.41%) | To recent high | -8.9% | To recent low | 13.4% | Market Cap | $165m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |